#MpviropackPlus: Real Life Study by Mohamed B Hashem in BJSTR

Abstract

Egypt has the highest prevalence of HCV worldwide. It is estimated to be 7.3% which is considered more than double the global prevalence that is estimated to be 3% according to the World Health Organization (WHO). The main #genotype in Egypt is genotype 4 [1]. For many years ago, HCV treatment remained a challenge, where the available regimens were the moderately potent but poorly tolerated combination of pegylated interferon (PegIFN) and #ribavirin for 24 or 48 weeks [2]. Using this combination, HCV genotype 4 patients had intermediate SVR rates (50-60%) [3]. Since 2011, multiple new drugs acting on specific #enzymaticsites throughout the HCV life cycle were developed (direct acting antiviral drugs DAAs). DAAs are more potent than the INF/RBV with bettersafety profile. DAAs are now widely available worldwide [4].

For more Biomedical open access journals please click on https://biomedres.us/

For more Biomedical Research and Reviews Articles on BJSTR

https://biomedres.us/abstracts/BJSTR.MS.ID.000918.php 

https://biomedres.us/fulltexts/BJSTR.MS.ID.000918.php 

#Mpviropack Plus: Real Life Study by Mohamed B Hashem in BJSTR